Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Bentley Pharmaceuticals (AMEX:BNT)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider | Financials
Location
65 Lafayette Road, 3rd Floor
North Hampton, NH 03862
Phone: (603) 964-8006
Fax: (603) 964-6889
Email: invrel@bentleypharm.com
Employees (last reported count): 209
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 54%
·Over the last 6 months:
 · one insider buy; 50.0K shares (0.7% of insider shares)
·Institutional: 13% (27% of float)
(15 institutions)
·Net Inst. Buying: 514.0K shares (+22.34%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Bentley Pharmaceuticals, Inc. is a drug delivery company specializing in the development of products based on proprietary drug delivery systems. The Company also has a commercial presence in Europe, where it manufactures, markets and distributes branded and generic pharmaceutical products. The Company owns rights to certain United States and international patents and related technology covering methods to enhance the absorption of drugs delivered to biological tissues. In Spain, the Company acquires, licenses or develops and registers late stage products, and manufactures, packages and distributes its own products and products under contract for other pharmaceutical companies. During 2000, 99% of the Company's revenues were derived from its operating subsidiaries, Laboratorios Belmac S.A. and Laboratorios Davur S.L., in Spain.
More from Market Guide: Expanded Business Description

Financial Summary
Bentley Pharmaceuticals, Inc. is engaged in the manufacturing, marketing and distribution of pharmaceutical products in Spain, with limited product distribution in the US. For the six months ended 6/30/01, sales rose 23% to $11.9 million. Net income totalled $2.1 million vs. a loss of $141 thousand. Revenues reflect an increase in sales in the Spanish generic drug market. Earnings reflect the inclusion of a $5 million gain on the sale of a drug license.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

James Murphy, 51
Chairman, Pres and CEO
$559K--  
Michael McGovern, 57
Vice Chairman
--  --  
Robert Stote, M.D., 61
Sr. VP, CSO
120K--  
Michael Price, 43
VP, CFO, Sec., Treasurer
229K--  
Robert Gyurik, 54
VP of Pharmaceutical Devel.
179K$4.3K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:BNTAs of 31-Aug-2001
Price and Volume
52-Week Low
on 21-Dec-2000
$3.563
Recent Price$7.10 
52-Week High
on 2-Oct-2000
$11.00 
Beta1.92 
Daily Volume (3-month avg)16.2K
Daily Volume (10-day avg)23.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-21.1%
52-Week Change
relative to S&P500
+5.8%
Share-Related Items
Market Capitalization$99.9M
Shares Outstanding14.1M
Float6.50M
Dividends & Splits
Annual Dividendnone 
Last Split: 1 for 10 on 24-July-1995
Per-Share Data
Book Value (mrq)$1.34 
Earnings (ttm)$0.08 
Earnings (mrq)-$0.04 
Sales (ttm)$1.50 
Cash (mrq)$0.26 
Valuation Ratios
Price/Book (mrq)5.32 
Price/Earnings (ttm)89.87 
Price/Sales (ttm)4.74 
Income Statements
Sales (ttm)$20.9M
EBITDA (ttm)$4.01M
Income available to common (ttm)$1.47M
Profitability
Profit Margin (ttm)7.0%
Operating Margin (ttm)15.6%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)5.58%
Return on Equity (ttm)8.14%
Financial Strength
Current Ratio (mrq)1.93 
Debt/Equity (mrq)0.08 
Total Cash (mrq)$3.66M
Short Interest
As of 8-Aug-2001
Shares Short171.0K
Percent of Float2.6%
Shares Short
(Prior Month)
0 
Short Ratio8.55 
Daily Volume20.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.